On February 16, 1956, these handwritten notes from weekly EMG case conference @MayoNeuroRes describe a patient with weakness, decrement, and facilitation. First written description of what would become Lambert-Eaton myasthenic syndrome #LEMS Notes in black from Dr. Lambert

Wow ! Simply wow - another chemotherapy free regimen for ph+ ALL Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia On day 84 - 100% CR and 89% MRD negative ashpublications.org/blood/article/…

Witness the extraordinary resolve of Dr. Vanita Noronha as she transforms her breast cancer experience into a story of hope and resilience. Watch the video now. 🔗 youtu.be/fNJg8fSrvmo?fe…

📢CAR T-cells for relapsed/refractory B-cell malignancies in India: phase 1/2 trial 📈Safety: no ICANS, low incidence of severe CRS, manageable haematological toxicities, 2 treatment-related deaths. 🔍Activity: 73% overall response rate.Rahul Purwar 👇 shorturl.at/x11Ip

Meet Romulus and Remus—the first animals ever resurrected from extinction. The dire wolf, lost to history over 10,000 years ago, has returned. Reborn on October 1, 2024, these remarkable pups were brought back to life using ancient DNA extracted from fossilized remains. Watch

Challenges in managing and reporting adverse events in haematological malignancies in low-income and middle-income countries - The Lancet Haematology thelancet.com/journals/lanha…

Finally in paper this work that was presented at last ASH! Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML | Blood | American Society of Hematology ashpublications.org/blood/article/…

ADCs are rapidly improving the way we treat every type of cancer. Their potential has been largely unleashed over the past 6 years— yet their technology is the result of a 100-year long, epic journey. Join Raffaele Colombo & me to uncover 10 milestones in the development of ADCs (🧵):

What’s up with Beta 2 microglobulin (B2M) and myeloma? Why is it the sole non-cytogenetic marker used in the new IMWG high risk definition? Why does it matter whether the creatinine is high or not? Thread 1/

1/ 🧪 The Era of In-Vivo CAR-T Has Arrived No leukapheresis. No lymphodepletion. No 3-week manufacturing delay. Just a vial and a vein. EsoBiotech’s in-vivo BCMA CAR-T has shown deep responses in myeloma after a single infusion. Here’s why that matters 🧵

Novak Djokovic’s daughter showing the Wimbledon crowd how to pump it up after her dad’s win 😂 Adorable 🥹

📢 Out in NEJM Evidence 👫N=1132 pts; age 18-60 🔹ND #AML 🔹Consolidation with IDAC vs HIDAC 🔹5-yr OS = 59% vs 58% 🔹Lower incidence of myelosuppressio & AEs with IDAC ➡️ IDAC non inferior to HIDAC #leusm OncoAlert evidence.nejm.org/doi/pdf/10.105…

British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

🔥 Cyclophosphamide (high dose) - for refractory ICANS post CAR-T from Tata Memorial Hospital Rahul Banerjee, MD, FACP Nikita Mehra 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM Rahul Purwar Ranjit Kumar Sahoo Gaurav Narula MD Prashant Mehta Dr Amol Akhade onlinelibrary.wiley.com/doi/10.1111/bj…

🚨 Refractory ICANS post-CAR-T? In a case of Grade 4 neurotoxicity unresponsive to steroids & anakinra, cyclophosphamide led to rapid neurological recovery without compromising CAR-T efficacy. Promising rescue for life-threatening ICANS Congrats Manan Vora, MD

As we drive this CAR more, better ways of steering & braking emerge! Great work Manan Lingaraj Nayak Hasmukh Jain and adult HL group Tata Memorial Hospital 👏🏻👏🏻👏🏻

Just published in CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better

Cyclophosphamide—A promising solution for refractory ICANS British Journal of Haematology share.google/NePwZEwiHQEc0K…